NO954342D0 - Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav - Google Patents

Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav

Info

Publication number
NO954342D0
NO954342D0 NO954342A NO954342A NO954342D0 NO 954342 D0 NO954342 D0 NO 954342D0 NO 954342 A NO954342 A NO 954342A NO 954342 A NO954342 A NO 954342A NO 954342 D0 NO954342 D0 NO 954342D0
Authority
NO
Norway
Prior art keywords
processes
preparation
well
erythropoietin analog
analog mixtures
Prior art date
Application number
NO954342A
Other languages
English (en)
Norwegian (no)
Other versions
NO954342L (no
Inventor
Gregory F Okasinski
Peter J Devries
Barry S Mellovitz
Joseph L Meuth
Verlyn G Schaefer
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of NO954342L publication Critical patent/NO954342L/no
Publication of NO954342D0 publication Critical patent/NO954342D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO954342A 1993-04-29 1995-10-30 Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav NO954342D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5507693A 1993-04-29 1993-04-29
PCT/US1994/004755 WO1994025055A1 (en) 1993-04-29 1994-04-29 Erythropoietin analog compositions and methods

Publications (2)

Publication Number Publication Date
NO954342L NO954342L (no) 1995-10-30
NO954342D0 true NO954342D0 (no) 1995-10-30

Family

ID=21995426

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954342A NO954342D0 (no) 1993-04-29 1995-10-30 Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav

Country Status (13)

Country Link
US (1) US5888772A (ko)
EP (1) EP0744953A4 (ko)
JP (1) JPH08509614A (ko)
KR (1) KR960701650A (ko)
CN (1) CN1125401A (ko)
AU (1) AU697453B2 (ko)
BR (1) BR9406490A (ko)
CA (1) CA2161651A1 (ko)
CZ (1) CZ286046B6 (ko)
FI (1) FI955128A0 (ko)
HU (1) HUT73876A (ko)
NO (1) NO954342D0 (ko)
WO (1) WO1994025055A1 (ko)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
KR100400637B1 (ko) * 1996-02-06 2004-03-10 씨제이 주식회사 생물학적으로유용한펩타이드
US5835382A (en) * 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
DE69736780T2 (de) 1996-08-02 2007-09-06 Ortho-Mcneil Pharmaceutical, Inc. Polypeptide mit einzelnem kovalent gebundenen n-terminalen wasserlöslichen polymer
US6967092B1 (en) 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
ES2221717T3 (es) * 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
ES2267263T3 (es) * 1998-04-15 2007-03-01 Emd Lexigen Research Center Corp. Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo.
ES2273497T3 (es) 1998-06-15 2007-05-01 Gtc Biotherapeutics, Inc. Proteina de fusion de la albumina serica humana de eritropoyetina analoga.
CA2352538A1 (en) * 1998-11-30 2000-06-08 Eli Lilly And Company Erythropoietic compounds
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US7410941B1 (en) 1999-04-13 2008-08-12 The Kenneth S. Warren Institute, Inc. Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
CN1235911C (zh) * 1999-08-09 2006-01-11 利思进药品公司 多细胞因子－抗体复合物
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
WO2001036489A2 (en) * 1999-11-12 2001-05-25 Merck Patent Gmbh Erythropoietin forms with improved properties
AU4314801A (en) 2000-02-11 2001-08-20 Lexigen Pharm Corp Enhancing the circulating half-life of antibody-based fusion proteins
AU7172901A (en) * 2000-06-29 2002-01-14 Lexigen Pharm Corp Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
CA2412277A1 (en) * 2000-09-08 2002-03-14 Gryphon Therapeutics, Inc. Synthetic erythropoiesis stimulating proteins
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
AU2001296354A1 (en) 2000-09-25 2002-04-02 Baylor College Of Medicine Improved system for regulation of transgene expression
US7767643B2 (en) * 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US6531121B2 (en) * 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
PT1366067E (pt) * 2001-03-07 2012-11-29 Merck Patent Gmbh Tecnologia de expressão para proteínas contendo uma unidade de anticorpo de isotipo híbrido
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
MXPA03009924A (es) * 2001-05-03 2004-01-29 Merck Patent Gmbh Anticuerpo recombinante especifico de tumor y uso del mismo.
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
ES2381025T3 (es) * 2001-12-04 2012-05-22 Merck Patent Gmbh Inmunocitocinas con selectividad modulada
MXPA05000063A (es) * 2002-07-01 2005-04-08 Kenneth S Warren Inst Inc Citocinas recombinantes protectoras de tejido y acidos nucleicos que las codifican para la proteccion, restauracion y mejora de celulas, tejidos y organos respondedores.
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
ES2343518T3 (es) * 2002-09-09 2010-08-03 Hanall Biopharma Co., Ltd. Polipeptidos interferon alfa modificados resistentes a proteasas.
WO2004055056A1 (en) * 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
CA2521273A1 (en) * 2003-04-02 2004-10-21 Epimmune Inc. Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
US7459152B2 (en) 2003-04-23 2008-12-02 Rush University Medical Center Erythropoietin administration to improve graft survival
ZA200603396B (en) * 2003-09-29 2007-11-28 Warren Pharmaceuticals Inc Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
CN1902222A (zh) * 2003-12-31 2007-01-24 默克专利有限公司 具有改善药物代谢动力学的Fc－促红细胞生成素融合蛋白质
DE102004004509B4 (de) 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
WO2007136752A2 (en) 2006-05-19 2007-11-29 Glycofi, Inc. Erythropoietin compositions
EP2120998B1 (en) 2006-11-28 2013-08-07 HanAll Biopharma Co., Ltd. Modified erythropoietin polypeptides and uses thereof for treatment
CN103113464B (zh) * 2007-07-02 2014-08-20 沈阳三生制药有限责任公司 天然人促红细胞生成素类似物
US20100298219A1 (en) * 2008-01-22 2010-11-25 Anthony Cerami Method of treating cancer, neoplastic disorders, and symptoms thereof with compounds
EP3103880A1 (en) 2008-02-08 2016-12-14 Ambrx, Inc. Modified leptin polypeptides and their uses
CN102232085A (zh) 2008-09-26 2011-11-02 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
US20100272816A1 (en) 2009-04-27 2010-10-28 Wolfgang Rudinger Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient
US20130034875A1 (en) * 2009-10-01 2013-02-07 Toto Ltd. Dna construct, and process for production of recombinant cho cell using same
CN102205114B (zh) * 2011-04-29 2012-12-12 中国人民解放军第三军医大学 促红细胞生成素来源肽在制备治疗神经系统自身免疫性疾病的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4835260A (en) * 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
DE3923963A1 (de) * 1989-07-20 1991-01-31 Behringwerke Ag Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung

Also Published As

Publication number Publication date
CZ284495A3 (en) 1996-02-14
JPH08509614A (ja) 1996-10-15
FI955128A (fi) 1995-10-27
EP0744953A4 (en) 1998-05-06
NO954342L (no) 1995-10-30
KR960701650A (ko) 1996-03-28
WO1994025055A1 (en) 1994-11-10
AU697453B2 (en) 1998-10-08
CZ286046B6 (cs) 1999-12-15
FI955128A0 (fi) 1995-10-27
HUT73876A (en) 1996-10-28
CN1125401A (zh) 1996-06-26
CA2161651A1 (en) 1994-11-10
HU9503088D0 (en) 1995-12-28
AU6778594A (en) 1994-11-21
EP0744953A1 (en) 1996-12-04
BR9406490A (pt) 1996-03-05
US5888772A (en) 1999-03-30

Similar Documents

Publication Publication Date Title
NO954342D0 (no) Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav
NO941104D0 (no) Asfaltblandinger, samt fremgangsmåte ved fremstilling derav
DE4494905T1 (de) Spektrometer
ES1026992Y (es) Barandilla, manija o analogo.
BR9400616A (pt) Processo para a preparação de 1,1,1,4,4,4-hexafluorbuteno-2
FR2709812B1 (fr) Procédé de combustion.
AU6245790A (en) Regulatory dna sequence
BR9400604A (pt) Processo para a preparação de 1,1,1,3,3-pentafluorpropano
FI943553A0 (fi) Upokas, erityisesti tukiupokas
GB2287953B (en) High stability, organic tanning processes
BR9407024A (pt) Processo para a preparação de 4,6-diamino-5-cianopirimidinas substituídas
NO902334L (no) Fremgangsmaate ved fremstilling av beholdere.
FI901546A0 (fi) Kompositioner innehaollande 2-tiocyanometyltiobensotiazol foer anvaendning i industriella mikrobiocider.
BR9007862A (pt) Tinturas de benzoxazina
NO931865D0 (no) Anordning ved kjernebor
NO950223D0 (no) Fremgangsmåte for fremstilling av kjeks, samt slik kjeks
NO900881D0 (no) Innretning ved piggdekk.
NO880100L (no) Fremgangsmaate ved utskiftning av anoder.
DE69002476D1 (de) Kationisches elektro-abscheidbares anstrichmittel.
ES1025981Y (es) Director-extractor de gases.
AT399492B (de) Versenkung, insbesondere verfahrbare einzelversenkung
FR2706142B1 (fr) Rasoir de sûreté.
AU7695094A (en) Alkyl-1-alkyl-4-hydroxy-2-oxo-1,8-naphthyridine-3-carboxylat es as anti-rheumatic agents
DE68902045D1 (de) Aerosollack.
KR950013225U (ko) 약탕 증류기

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application